ARS Pharmaceuticals, Inc. (SPRY) financial statements and ratios from SEC XBRL: revenue $84.28M (TTM), net margin -203.3%, revenue growth 114.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $84.28M |
| Net Margin | -203.3% |
| Revenue Growth (YoY) | 114.2% |
| EPS Growth (YoY) | 37.0% |
| FCF Growth (YoY) | 53.7% |
| Price / Book | 43.65 |
| Price / Sales | 4.67 |
| FCF Yield | -36.0% |
| Altman Z-Score | -0.37 (distress) |
| Sector P/E (Healthcare) | 21.7 |
SPRY overview · SPRY earnings · SPRY KPIs · SPRY investor relations · SPRY ownership · SPRY peers · SPRY filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.